Malaria contributes to the most widespread infectious diseases worldwide. Even though
current drugs are commercially available, the ever-increasing drug resistance problem by …

Ever increasing drug resistance by Plasmodium falciparum, the most virulent of human
malaria parasites, is creating new challenges in malaria chemotherapy. The entire genome …

Though morbidity and mortality due to malaria have declined in the last 15 years, emerging
resistance to first-line artemisinin-based antimalarials, absence of efficacious vaccines and …

Malaria is one of the neglected infectious diseases, and drugs are the first line of action
taken against the onset of malaria as therapeutics. The drugs can be of either natural or …

In the fight against malaria new medicines are an essential weapon. For the parts of the
world where the current gold standard artemisinin combination therapies are active …

Despite immense efforts to combat malaria in tropical and sub-tropical regions, the potency
of this vector-borne disease and its status as a major driver of morbidity and mortality remain …

Despite being one of the most prevalent tropical diseases, for many years malaria was not a
commercial priority for the pharmaceutical industry. However, in response to the emergence …

Antimalarial drug discovery has until recently been driven by high‐throughput phenotypic
cellular screening, allowing millions of compounds to be assayed and delivering clinical …

Malaria caused by Plasmodium parasites kills approximately 1-3 million people and causes
disease in 300-500 million people annually throughout the world. The current approaches to …

Plasmodium species are evolutionarily distant from model eukaryotes, and as a
consequence they exhibit many non-canonical cellular processes. In the post-genomic era …